Standard & Poor’s has affirmed its ‘A-‘ counterparty credit and financial strength ratings and negative outlook on Amedex Insurance Co.
Standard & Poor’s subsequently withdrew the ratings at the company’s request. The ratings reflected Amedex’s good business position as a niche provider of major medical products in Latin America, favorable operating performance, and strong capitalization.
These positive factors are offset by Amedex’s limited size, declining enrollment trends, new business risk through Amedex Bermuda, and high operating expenses, which are the direct consequence of its target market and high level of service provided.
Was this article valuable?
Here are more articles you may enjoy.
New York Homes Most Exposed to Hurricane Risk, Beating Miami
Trump Set to Sign AI Cybersecurity Directive as Soon as Thursday
Adani Enterprises Reaches $275 Million Settlement With Treasury
‘Big Tobacco’ Moment for Cannabis: What Insurers Need to Know About Murray v. Cresco